Peptide Clinical Trials: 36 Records & Study Finder (2026)

By Peptide Care Index · Updated October 2026

This peptide clinical trials reference covers 36 selected study records, with exact drug names, recruitment labels and links to the original entries. Peptide Care Index’s October 2026 check found posted registry results for 13 of them. Use the tables to find a study—and see which similar names must stay separate. View the checked records.

What are the key peptide clinical trials statistics?

• 36 unique study records are included in Peptide Care Index’s selected ClinicalTrials.gov reference, checked October 14, 2026. This is a reference set, not a count of all peptide trials worldwide. Full table.
  Copy stat, source and deep link
• 13 of the 36 selected records have posted ClinicalTrials.gov summary results, according to our October 14, 2026 extraction. The other 23 do not have posted registry results; that does not mean no paper or other report exists. Results check.
  Copy stat, source and deep link
• 3 of the 36 selected records carry the registry label “Recruiting” as checked October 14, 2026. One other is “Active, not recruiting.” Neither a listing nor an old status guarantees a place at a study site. Recruiting records.
  Copy stat, source and deep link
• 3 retained BPC-157-related records have no posted registry results, according to our October 14, 2026 check: one old status-unknown record, one completed gummy-formulation record, and one planned surgical-recovery study. A separate unresolved record is held out. BPC-157 records.
  Copy stat, source and deep link
• 19 selected records concern full-length thymosin beta-4 formulations, according to our October 14, 2026 classification. We keep them separate from the TB-500 fragment; they are not 19 TB-500 trials. Molecule check.
  Copy stat, source and deep link
• 88 participants are reported as actual enrollment in the completed CB4211 study, NCT03998514, whose last registry update was May 11, 2021. CB4211 is a MOTS-c analogue, not native MOTS-c. Record.
  Copy stat, source and deep link
• No eligible named KPV intervention record was found in our documented KPV and synonym searches, checked October 14, 2026. This is a scoped registry-search finding, not proof that no human research exists anywhere. Search scope.
  Copy stat, source and deep link
• 1 excluded TB-500 search result explicitly describes itself as fictional in its own registry summary. We do not count NCT07487363 as a real recruiting study. Exclusion evidence.
  Copy stat, source and deep link

Which peptide clinical trials should I look up?

Start with the exact molecule, then check the study’s status and results. The 36 selected records below cover several different research jobs. A related molecule, a skin-care blend and a study measuring a peptide in blood do not answer the same question.

Source: Peptide Care Index classification of the linked ClinicalTrials.gov records. Counts refer only to this selected reference. Studies with more than one drug are counted once by NCT number.

For a wider search, use ClinicalTrials.gov. Enter the molecule and your condition, then use its location and recruitment filters. The direct record links here also lead to the study’s contacts and locations. Our peptide comparison chart covers the broader evidence and product-identity questions.

Which selected peptide trials are listed as recruiting?

Three included records are labeled Recruiting in the registry snapshot. Confirm the current position with the study site. A study-level label can remain unchanged after its listed completion estimate, and a site can have no open places even while the wider trial is recruiting.

Source: each linked registry record, checked October 14, 2026; UC San Diego provides the additional site-level check for SYNERGY-Outcomes. Enrollment targets belong to whole studies, not to each drug arm or each site.

To find peptide clinical trials near you, open a record, check Contacts and Locations, and read the site-specific status. Ask whether that site is accepting people with your condition. Review participation with your own healthcare professional. NIH’s trial-finding guide explains this process.

What do all 36 selected trial records say?

These tables preserve the registry’s phase, status, enrollment type and last update. “Reported actual” means the sponsor’s registry entry reports actual enrollment; it is not our independent count of people treated. “Estimated” is a plan. Enrollment is for the whole study and can include placebo or comparator participants.

An NCT number identifies one registry record. A Phase 2 / Phase 3 entry is one study with a combined phase label. “Not applicable” and a missing enrollment type remain as reported. The downloadable CSV adds full titles, interventions, sponsors, countries, source URLs and interpretation notes.

Selected molecule and formulation records

Source: each row links to its original ClinicalTrials.gov record; all checked October 14, 2026. The reference is selected, not a census. GHK-Cu is a multiingredient/device record. CB4211 is an analogue. CagriSema and the master protocol contain multiple drugs.

Full-length thymosin beta-4 formulation records

The 19 records below are grouped as thymosin beta-4 formulations. They stay separate from the TB-500 fragment. RGN-259 is an eye formulation; RGN-137 is a skin gel; RGN-352 is an injectable formulation. The route and product matter as much as the family name. RegeneRx’s RGN-137 description and NCT01387347 support these product distinctions.

Source: linked ClinicalTrials.gov records, checked October 14, 2026. A terminated study can have results. A withdrawn plan reporting zero enrollment is not a study that exposed participants to the peptide.

Does a completed trial mean results are available?

No. 13 of the 36 selected records have posted ClinicalTrials.gov summary results; 23 do not. Completion, results posting and journal publication are separate checks. The registry’s results flag does not tell us whether the treatment worked.

Source: Peptide Care Index count of the registry results flags in the 36-row dataset, checked October 14, 2026. This selected set does not estimate results-reporting rates for all peptide research.

Download PNG

Two useful checks are the retatrutide phase 2 paper, which reports 338 adults, and the SELECT semaglutide paper, which reports 17,604 participants. Both correspond to records here with posted registry results. Their findings belong to their own populations and designs; they do not prove a benefit for every peptide.

To look for results, check the record’s Results Posted area and then search its NCT number in PubMed. NLM explains how the registry separates record details and results and how to find published trial results. We have not run a systematic publication search for every record in this reference.

Why do peptide trial counts disagree?

A count changes when its rules change. This reference counts 36 unique NCT records, including clearly labeled related molecules and formulations. It does not add the same master protocol once for retatrutide and again for tirzepatide, or turn a study measuring a peptide into a study giving that peptide.

Source: the linked registry records and our record-level classification; API metadata defines the fields used.

What do the BPC-157 clinical trial records show?

The three retained BPC-157-related records have no posted registry summary results as checked October 14, 2026. They are not three completed randomized trials. One is status unknown, one reports a completed gummy-formulation study, and one has not started recruiting.

• PCO-02 / Bepecin, NCT02637284: Phase 1; estimated enrollment 42; current status Unknown. The last record update was December 22, 2015. Do not turn that estimate into 42 people proved to have received BPC-157.
• Parlay Recover Peptide Gummies, NCT07752381: a single-group, unblinded formulation study; reported actual enrollment 40; no registry results. The entry was first posted August 7, 2026, after its reported November 1, 2025 completion. Its “dietary supplement” intervention label does not establish lawful supplement status or drug approval.
• Rotator-cuff recovery, NCT07803250: Phase 1, Not yet recruiting; structured estimated enrollment 30; planned start January 2027. Its narrative mentions a different participant count and conflicts over the comparator. We preserve the structured estimate and make no claim about the comparator design.

A fourth broad-name match, NCT07437547, is held out for the provenance reason below. This is why our retained count differs from an unfiltered four-record search. BPC-157 news has a separate broad-name record snapshot. For the access question, how to get BPC-157 separates trial participation from commercial offers. The BPC-157 capsules page addresses the formulation question; an oral-study plan does not establish that every oral product works.

Are TB-500 trials the same as thymosin beta-4 trials?

No. The 19 thymosin beta-4 formulation records in this reference are not counted as 19 trials of the TB-500 fragment. Full-length thymosin beta-4 and the fragment are different molecular forms, and eye, skin and injectable products answer different questions. FDA’s TB-500 briefing document and the RGN-259 registry description identify the forms.

The TB-500 record NCT07487363 is excluded because its summary explicitly calls it fictional. A long list of thymosin beta-4 trials cannot fix that problem. Nor can an eye-drop result establish that a fragment injection helps an injured tendon.

Is CB4211 a human trial of MOTS-c?

CB4211 is a related analogue—a modified molecule—not native MOTS-c. Its completed Phase 1 record, NCT03998514, reports actual enrollment of 88 and no posted registry summary results. CohBar’s SEC-filed description identifies the analogue relationship.

Our MOTS-c searches also returned studies that measure the body’s own MOTS-c, rather than administer it. Those are excluded from direct intervention evidence. Native-MOTS-c record NCT07505745 is held out pending provenance checks; we do not turn that decision into a claim that no human MOTS-c research exists anywhere.

Did the search find a KPV human trial?

No eligible intervention record was retained from our KPV, Lys-Pro-Val and Lysine-Proline-Valine searches on October 14, 2026. The exact KPV intervention search returned zero records. The two expanded names each returned four broad matches, but the reviewed records did not administer the named KPV peptide.

The search manifest gives the exact queries. The exclusion log gives the record-level reasons. This finding covers those registry searches; it does not cover every registry, unpublished experiment or paper worldwide.

Does the GHK-Cu record test GHK-Cu alone?

No. NCT05932732 reports 27 actual participants in a device-plus-multiingredient treatment. Its ReGen-GF booster includes Cu-GHK and other ingredients. The design cannot isolate GHK-Cu’s effect, and its registry-reported Phase 4 label does not establish FDA approval of GHK-Cu.

A separate X39 patch record measures circulating GHK/GHK-Cu. That is not administration of the peptide, so it is in the exclusion log. The standalone GHK-Cu gel record from the sponsor discussed below is held out, not silently counted as an available trial.

Which records were excluded or held out?

The specialist-search log contains 13 excluded or held-out matches. One explicitly describes itself as fictional. Three others are held out as an editorial judgment pending independent provenance checks; we have not proved those three fictional. The remaining entries do not administer the named peptide.

Source: complete ClinicalTrials.gov records and API payloads, read October 14, 2026. The holdouts are our inclusion decisions, not findings of misconduct or an agency ruling. The log is a record of this specialist screen, not an exhaustive list of every excluded peptide-related entry in the registry.

What do Phase 1, Phase 2 and Phase 3 mean?

Phase describes a study’s role in drug development; status describes where that study stands. A Phase 3 study may be recruiting, completed or stopped. Neither the phase field nor a registry listing is a drug-approval decision.

Source: FDA’s clinical research overview; record fields remain as reported. The table describes purpose, not a fixed study size or a guarantee of study quality.

For the separate regulatory question, see is BPC-157 FDA approved?. NIH also states that listing a study does not mean the U.S. government has evaluated it.

How was this peptide clinical trials reference built?

We read complete ClinicalTrials.gov API records on October 14, 2026. The final reference combines 24 retained records from a specialist molecule screen with 12 selected drug-development and human-study examples. We deduplicated the combined set by NCT number: 24 + 12 = 36 unique records.

1. Define the job. Cover BPC-157, the TB-500/full-length thymosin beta-4 distinction, MOTS-c/CB4211, KPV and GHK-Cu, then add examples across peptide drug development. We did not attempt an all-peptide census.
2. Search the specialist names. The manifest records 28 term queries, including aliases and formulation codes. Each query’s full returned record set was read; none needed a second page. This uncapped specialist retrieval does not make the separately selected broader examples exhaustive.
3. Check the intervention. Read names, other names, ingredient descriptions, summaries and study design. Keep an analogue, formulation or multi-drug study visibly labeled. Remove measurement-only matches and apply the stated integrity exclusions.
4. Extract the registry fields. Copy NCT ID, phase, status, enrollment count and type, sponsor, record-update date and results flag. Keep the sponsor’s status-verification month separate from our check date. The API field metadata documents these fields.
5. Add the selected examples. Read the 12 exact NCT records in the download, rather than using keyword-search counts as a proxy for the broader peptide field. The SYNERGY-Outcomes record is counted once, although it lists more than one drug.
6. Count only this set. Results posted: 13 Yes and 23 No. Recruiting: 3. We do not sum enrollment into a total of people treated or use this selected set to estimate the whole field.
7. Preserve the evidence. The download carries record URLs and check dates. The companion exclusion log, specialist-query manifest and source snapshots preserve the scope and decisions behind the page.

Our methodology and editorial standards describe the publication’s wider standards. No clinician review is claimed for this reference.

What can this dataset tell us—and what can’t it?

It can show what the 36 selected registry records reported when checked. It cannot prove that a study took place exactly as described, that a site has an open place, or that a treatment is safe or effective. Sponsors and investigators supply registry information, as NLM explains.

This is not a systematic review, an approval list, a ranking of peptides, or a complete survey of global trial registries. It leaves out many peptide medicines, indications and records. The broader examples were selected for useful comparisons, so the 13-of-36 results count is not a general reporting-rate estimate.

Missing registry results do not prove missing publications. Reported actual enrollment is not the number exposed to the active drug. A trial of an eye drop, a blend, an analogue or a specific disease population does not establish the result for a different product or use.

If you are checking a clinic’s access claim, Find My Peptide Path helps you prepare questions about the exact product and source. It is a self-guided research resource, not a trial-enrollment service.

How can I cite this page and download the data?

For the original classification and selected-record counts, cite Peptide Care Index and name the snapshot date. For a trial’s design or result, cite its registry record or original paper as well. This preserves the difference between our analysis and the underlying research.

Ready-to-copy citation

Peptide Care Index. Peptide Clinical Trials: 36 Records & Study Finder (2026). Research snapshot checked October 14, 2026. https://peptidecareindex.com/research/peptide-clinical-trials/

Downloads

• 36-row trial reference CSV
• Excluded and held-out specialist records CSV
• Specialist search manifest CSV
• Results chart PNG · SVG
• Data dictionary

You may reuse our original classification, analysis text and chart with credit to Peptide Care Index by name; underlying records, abstracts and third-party materials retain their own attribution and terms.

What else do people ask about peptide clinical trials?

How many peptide clinical trials are there?

This page contains 36 selected records, not a worldwide total. An all-peptide count needs a stated molecule list, aliases, registry scope, intervention-screening rules and deduplication. A raw search total cannot answer that question on its own.

Can I join a peptide clinical trial?

Three included records are labeled Recruiting in this snapshot. Eligibility depends on the trial and site; the study team must confirm it. Use the official record’s contacts rather than treating a paid clinic consultation or product purchase as trial enrollment.

Are there BPC-157 human clinical trials?

There are registered BPC-157-related study records. The three retained here have no posted registry results and have very different designs and status labels. Their existence does not establish an effective treatment, and this registry screen is not a count of every human BPC-157 publication.

Is a peptide with an NCT number FDA approved?

No approval conclusion follows from an NCT number. It identifies a registry record. NIH says a listing does not mean the U.S. government has evaluated the study; drug approval is a separate question.

Does “no results posted” mean the peptide does not work?

No. It means no summary results are posted in the registry record checked here. It does not prove a negative result, no publication, or no human experience; those require separate evidence checks.

Which sources support this reference?

All sources below were checked October 14, 2026. Registry-update dates are preserved separately in the tables and download. Each trial has both a human-readable record URL and an API source in the CSV.

1. ClinicalTrials.gov NCT02637284 — PCO-02 - Safety and Pharmacokinetics Trial. Checked 2026-10-14; record last updated 2015-12-22.
2. ClinicalTrials.gov NCT07752381 — A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery. Checked 2026-10-14; record last updated 2026-08-07.
3. ClinicalTrials.gov NCT07803250 — Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery. Checked 2026-10-14; record last updated 2026-09-03.
4. ClinicalTrials.gov NCT03998514 — A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. Checked 2026-10-14; record last updated 2021-05-11.
5. ClinicalTrials.gov NCT00267527 — A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. Checked 2026-10-14; record last updated 2006-10-16.
6. ClinicalTrials.gov NCT05567796 — A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight. Checked 2026-10-14; record last updated 2026-09-30.
7. ClinicalTrials.gov NCT00311766 — A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa. Checked 2026-10-14; record last updated 2014-05-12.
8. ClinicalTrials.gov NCT00382174 — Study of Thymosin Beta 4 in Patients With Pressure Ulcers. Checked 2026-10-14; record last updated 2010-02-01.
9. ClinicalTrials.gov NCT00598871 — A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds. Checked 2026-10-14; record last updated 2015-07-08.
10. ClinicalTrials.gov NCT00743769 — A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers. Checked 2026-10-14; record last updated 2017-04-17.
11. ClinicalTrials.gov NCT00832091 — Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers. Checked 2026-10-14; record last updated 2010-03-30.
12. ClinicalTrials.gov NCT01311518 — A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction. Checked 2026-10-14; record last updated 2021-09-22.
13. ClinicalTrials.gov NCT01387347 — Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye. Checked 2026-10-14; record last updated 2015-07-10.
14. ClinicalTrials.gov NCT01393132 — Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye. Checked 2026-10-14; record last updated 2015-12-23.
15. ClinicalTrials.gov NCT02597803 — Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1. Checked 2026-10-14; record last updated 2019-10-17.
16. ClinicalTrials.gov NCT02600429 — Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1. Checked 2026-10-14; record last updated 2023-08-30.
17. ClinicalTrials.gov NCT02974907 — Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2. Checked 2026-10-14; record last updated 2022-01-05.
18. ClinicalTrials.gov NCT03578029 — Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa. Checked 2026-10-14; record last updated 2022-08-22.
19. ClinicalTrials.gov NCT03937882 — Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3. Checked 2026-10-14; record last updated 2026-08-28.
20. ClinicalTrials.gov NCT04555824 — A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers. Checked 2026-10-14; record last updated 2020-09-29.
21. ClinicalTrials.gov NCT04555850 — A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers. Checked 2026-10-14; record last updated 2020-09-29.
22. ClinicalTrials.gov NCT05485818 — Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction. Checked 2026-10-14; record last updated 2022-08-03.
23. ClinicalTrials.gov NCT05555589 — Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2. Checked 2026-10-14; record last updated 2025-12-23.
24. ClinicalTrials.gov NCT05984134 — Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction. Checked 2026-10-14; record last updated 2024-06-21.
25. ClinicalTrials.gov NCT07586865 — Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction. Checked 2026-10-14; record last updated 2026-05-14.
26. ClinicalTrials.gov NCT05932732 — Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.. Checked 2026-10-14; record last updated 2024-10-24.
27. ClinicalTrials.gov NCT00672074 — Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus. Checked 2026-10-14; record last updated 2017-04-14.
28. ClinicalTrials.gov NCT02225366 — Intratumoral Injections of LL37 for Melanoma. Checked 2026-10-14; record last updated 2021-12-09.
29. ClinicalTrials.gov NCT04881760 — A Study of LY3437943 in Participants Who Have Obesity or Are Overweight. Checked 2026-10-14; record last updated 2023-09-13.
30. ClinicalTrials.gov NCT05929066 — A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight. Checked 2026-10-14; record last updated 2026-08-21.
31. ClinicalTrials.gov NCT07165028 — A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes). Checked 2026-10-14; record last updated 2026-10-08.
32. ClinicalTrials.gov NCT03574597 — Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity. Checked 2026-10-14; record last updated 2024-08-30.
33. ClinicalTrials.gov NCT06066515 — A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight. Checked 2026-10-14; record last updated 2026-03-12.
34. ClinicalTrials.gov NCT02196831 — Tesamorelin Effects on Liver Fat and Histology in HIV. Checked 2026-10-14; record last updated 2020-01-27.
35. ClinicalTrials.gov NCT06554717 — Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV. Checked 2026-10-14; record last updated 2026-05-19.
36. ClinicalTrials.gov NCT02867267 — The Efficacy and Safety of Ta1 for Sepsis. Checked 2026-10-14; record last updated 2023-04-10.
37. ClinicalTrials.gov API field metadata. Checked 2026-10-14.
38. NIH: Finding a Clinical Trial. Checked 2026-10-14.
39. NLM: Study Record Information Displays. Checked 2026-10-14.
40. NLM: How do I find the results of a clinical trial?. Checked 2026-10-14.
41. FDA: Step 3, Clinical Research. Checked 2026-10-14.
42. CohBar: CB4211 analogue identity, SEC-filed issuer release. Checked 2026-10-14.
43. RegeneRx: RGN-137 formulation identity. Checked 2026-10-14.
44. FDA: July 2026 TB-500 briefing document. Checked 2026-10-14.
45. Registry NCT07487363: self-described fictional entry, excluded. Checked 2026-10-14.
46. UC San Diego: SYNERGY-Outcomes site information. Checked 2026-10-14.
47. Jastreboff et al.: retatrutide phase 2, 2023, DOI 10.1056/NEJMoa2301972. Checked 2026-10-14.
48. Lincoff et al.: SELECT semaglutide, 2023, DOI 10.1056/NEJMoa2307563. Checked 2026-10-14.

What changed: October 14, 2026 — created the selected 36-record reference, separated related molecules and formulations, and documented fictional, measurement-only and unresolved records outside the included lookup.